Uniting Biotech & Pharma to Fuel the Next Wave of Neurodegenerative Drug Discovery, Translation & Clinical Progress

After a 17-year hiatus in drug approvals for neurodegeneration, disease-modifying drugs for AD have finally broken the ice. With Lecanemab’s clinically proven 30% reduction in cognitive decline receiving the green light from the FDA & PMDA and Eli Lilly’s Donanemab hot on their heels for approval, 58 new trials entering the pipeline this year, and the alpha-synuclein self-seeding assay changing the game for PD drug development.

The 12th Alzheimer’s & Parkinson’s Drug Development Summit is indisputably the ultimate industry-focused meeting dedicated to sharing the hottest unpublished AD & PD research from senior biopharma KOLs you won’t hear anywhere else, with deep-dive content all the way from early discovery through to late phase trials and approvals.

This April, join 150+ senior industry leaders across discovery, preclinical, biomarker, translational, clinical, and commercial this year from Eli Lilly, Biogen, Eisai, Abbvie, Merck, Michael J. Fox Foundation, Acumen, Vigil Neuroscience, and many more….

Expert Speakers Include:
pallavi - speaker headshot

Pallavi Sachdev

Executive Director

Eisai

holly - speaker headshot

Holly Soares

Vice President & Head of Precision Medicine

Pfizer

thierry - speaker headshot

Thierry Bussiere

Scientific DIrector

Biogen

eric - speaker headshot

Eric Siemers

Chief Medical Officer

Acumen Pharmaceuticals

gosia - headshot

Gosia (Malgorzata) Gonciarz

Vice President - Genetic Medicine

Eli Lilly & Co.

samantha - speaker headshot

Samantha Hutten

Director, Discovery & Translational Research

The Michael J. Fox Foundation for Parkinson's Research

rouba - speaker headshot

Rouba Kozak

Global Biomarker & Diagnostics Leader of Neuroscience

Novartis AG

fiona - speaker headshot

Fiona Elwood

Vice President & Disease Area Stronghold Lead, Neurodegeneration

Janssen

DOWNLOAD THE FULL EVENT GUIDE TO DISCOVER:

  • 53+ Expert Biotech & Pharma Neuroscientist Speakers
  • 3 Days of Cutting Edge Content
  • 3 New Tracks Spanning Neuroscience Discovery, Translation, Clinical & Commercial Topics
  • Brand New Blood-Based Biomarkers Focus Day
Attending Companies Include:
Companies Attending Logo Cloud
What Have Your Peers Said?

"Alzheimer’s & Parkinson’s Drug Development Summit is a great venue to develop meaningful collaborations in a pre-competitive environment to narrow the unmet gap and truly address patient needs." - Executive Director, Eisai

Previous attending company
Previous attending company

"This meeting has a range of presenters throughout various industry organizations. Topics cover a wide breadth of information on critical topics from the bench to the clinic for Alzheimer’s and Parkinson’s diseases, including recent advances in the field as well as areas that require further
advancement." -
Associate Scientific Director, Biogen

"Access to the most up-to-date progress in an exciting and fast-paced field." - Chief Executive Officer, Aprinoia

Testimonials logo - aprinoia
Testimonials logo - seelos

"This event features an intimate setting which gives you the opportunity to talk to your peers and delve into the details in depth to make it a very productive, concentrated, and focused program that makes it very attractive venue for learning the cutting edge of the field and casual interactions with great speakers and leaders in the arena." - VP & Head of Non-Clinical & Translational Research, Seelos Therapeutics

Our 2024 Partners:
Untitled design (1)
AlamarDropLogo_4c
NeuroLogo
Elixirgen 2024 Partner
Psychogenics 2024 partner
Neuro-Sys 2024 Partner
cnd
Sapient-Logo-Vertical-Full-Color-No-Background
Enigma Biomedical Group, USA Logo (Blue)
Quanterix-Logo 2024 Partner
bioneer 2024 Partner
Untitled design (2)
ALMAC Logo
Bit bio - 2024 Partner
Catalent 2024 Partner
Worldwide - 2024 partner
Our 2024 Media Partners:
The_Michael_J._Fox_Foundation_logo.svg
Journal of Alzheimer's Disease
Journal of Parkinson's Disease
Other Events in the World CNS Series